medigraphic.com
Colegio de Medicina Interna de México.

2020, Number 2

<< Back Next >>

Med Int Mex 2020; 36 (2)

Recommendations of the use of continuous monitoring and assessment of glycemic variability in diabetes

Lavalle-González FJ, Antillón-Ferreira C, Flores-Caloca O, Márquez-Rodríguez E, Yépez-Rodríguez AE, De la Garza-Hernández N, Martínez Ramos-Méndez A, Faradji-Hazán RN, Almeda-Valdés P, Mejía-Benítez A

Language: Spanish
References: 24
Page: 185-198
PDF size: 304.05 Kb.


ABSTRACT

In the last decade there have been important advances in the development of new technologies for the adjustment of therapy in patients with diabetes in order to avoid or reduce the risk of acute and chronic complications. Nowadays we can use the continuous glucose monitoring (CGM) that allows the detection of its variation during 24 hours a day, as well as episodes of hyperglycemia and hypoglycemia placing it as a novel and flexible option to reach and maintain glycemic control in these patients. The capillary self-monitoring shows specific information of the moment in which the glucose is measured; however, there are variations during the day and night (glycemic variability) that normally pass unnoticed. The behavior of glucose in patients with diabetes is complex and multifactorial; there are variables such as diet, exercise and associated comorbidities that must be carefully monitored. Therefore, CGM systems are useful to know the behavior of glucose during 24 hours and consequently, the physician can transmit to their patients the knowledge for interpretation and decisions based on the individualized needs of each patient. This paper presents recommendations of experts on the use of CGM, interpretation of data and their translation in therapeutic decisions.


REFERENCES

  1. Standards of Medical Care in Diabetes – 2019. Diabetes Care 2019;42(Suppl.1):S1:193.

  2. Diabetes. World Health Organization available from https:// www.who.int/diabetes/en/. Revisado el 19 de diciembre de 2018.

  3. Faradji Hazán RN, Sainz de la Maza Viadero E, Antillón Ferreira C, de la Garza Hernández N, Flores Caloca O, Gabriela García Galván, y col. Manual de procedimientos para el manejo de microinfusoras de insulina. Rev Endocrinol Nutr 2019;6:59-91.

  4. Kaufman FR, Gibson LC, Halvorson M, Carpenter S, Fisher LK, Pitukcheewanont P. A pilot study of the continuous glucose monitoring system: clinical decisions and glycemic control after its use in pediatric type 1 diabetic subjects. Diabetes Care 2001;24(12):2030-4. DOI: 10.2337/diacare. 24.12.2030.

  5. Aleppo G, Webb K. Continuous glucose monitoring integration in clinical practice: A stepped guide to data review and interpretation. J Diabetes Sci Technol 2019 Jul;13(4):664- 673. doi: 10.1177/1932296818813581.

  6. Gómez AM, Carrillo DCH, Taboada L, Rebolledo Del Toro M. Relevancia del monitoreo continuo de glucosa en la práctica clínica: revisión de la evidencia. Revista Colombiana de Endocrinología, Diabetes y Metabolismo 2018;5(3):33-41. http://revistaendocrino.org/index.php/ rcedm/article/view/432.

  7. Danne T, Nimri R, Battelino T, Bergenstal RM, Close KL, DeVries JH et al. International consensus on use of continuous glucose monitoring. Diabetes Care 2017, 40(12), 1631-1640. https://doi.org/10.2337/dc17-1600.

  8. Lagarde WH, Barrows FP, Davenport ML, Kang M, Guess HA, Calikoglu AS. Continuous subcutaneous glucose monitoring in children with type 1 diabetes mellitus: a single-blind, randomized, controlled trial. Pediatr Diabetes 2006;7(3):159- 64. DOI: 10.1111/j.1399-543X.2006.00162.x.

  9. Park C, Le QA. The effectiveness of continuous glucose monitoring in patients with type 2 diabetes: a systematic review of literature and meta-analysis. Diabetes Technol Ther 2018;20(9):613-621. doi: 10.1089/dia.2018.0177.

  10. Scheiner G. Practical CGM. A Guide to Improving Outcomes through Continuous Glucose Monitoring. American Diabetes Association (ADA), editor. Alexandria, Virginia, United States of America; 2015. 102 p.

  11. Matthaei S, DeAlaiz RA, Bosi E, Evans M, Geelhoed- Duijvestijn N, Joubert M. Consensus recommendations for the use of Ambulatory Glucose Profile in clinical practice. Br J Diabetes Vasc Dis 2014;14(4):153-157.

  12. Kudva YC, Ahmann AJ, Bergenstal RM, Gavin JR 3rd, Kruger DF, Midyett LK, et al. Approach to using trend arrows in the freestyle libre flash glucose monitoring systems in adults. J Endocr Soc 2018;2(12):1320-1337. doi: 10.1210/ js.2018-00294.

  13. Abraham MB, Jones TW, Naranjo D, Karges B, Oduwole A, Tauschmann M, et al. ISPAD Clinical Practice Consensus Guidelines 2018: Assessment and management of hypoglycemia in children and adolescents with diabetes. Pediatr Diabetes 2018;19 Suppl 27:178-192. doi: 10.1111/ pedi.12698.

  14. Karges B, Kapellen T, Wagner VM, Steigleder-Schweiger C, Karges W, Holl RW, et al. Glycated hemoglobin A1c as a risk factor for severe hypoglycemia in pediatric type 1 diabetes. Pediatr Diabetes 2017;18(1):51-58. doi: 10.1111/ pedi.12348.

  15. Oyer DS. The science of hypoglycemia in patients with diabetes. Curr Diabetes Rev 2013;9(3):195-208. DOI: 10.2174/15733998113099990059.

  16. Oskarsson P, Antuna R, Geelhoed-Duijvestijn P, Krӧger J, Weitgasser R, Bolinder J. Impact of flash glucose monitoring on hypoglycaemia in adults with type 1 diabetes managed with multiple daily injection therapy: a pre-specified subgroup analysis of the IMPACT randomised controlled trial. Diabetologia 2018;61(3):539-550. doi: 10.1007/ s00125-017-4527-5.

  17. Haak T, Hanaire H, Ajjan R, Hermanns N, Riveline JP, Rayman G. Flash glucose-sensing technology as a replacement for blood glucose monitoring for the management of insulintreated type 2 diabetes: a multicenter, open-label randomized controlled trial. Diabetes Ther 2017;8(1):55-73. doi: 10.1007/s13300-016-0223-6.

  18. Haak T, Hanaire H, Ajjan R, Hermanns N, Riveline JP, Rayman G. Use of flash glucose-sensing technology for 12 months as a replacement for blood glucose monitoring in insulintreated type 2 diabetes. Diabetes Ther 2017;8(3):573-586. doi: 10.1007/s13300-017-0255-6.

  19. Biester T, Kordonouri O, Holder M, Remus K, Kieninger- Baum D, Wadien T, et al. “Let the algorithm do the work”: reduction of hypoglycemia using sensor-augmented pump therapy with predictive insulin suspension (SmartGuard) in pediatric type 1 diabetes patients. Diabetes Technol Ther 2017;19(3):173-182. doi: 10.1089/dia.2016.0349.

  20. Borot S, Benhamou PY, Atlan C, Bismuth E, Bonnemaison E, Catargi B, et al. Practical implementation, education and interpretation guidelines for continuous glucose monitoring: A French position statement. Diabetes Metab 2018;44(1):61-72. doi: 10.1016/j.diabet.2017.10.009.

  21. Monnier L, Colette C. Glycemic variability: should we and can we prevent it? Diabetes Care 2008;31(Suppl 2):S150-4. doi: 10.2337/dc08-s241.

  22. Siegelaar SE, Holleman F, Hoekstra JB, DeVries JH. Glucose variability; does it matter? Endocr Rev 2010;31(2):171-82. doi: 10.1210/er.2009-0021.

  23. Hirsch IB, Brownlee M. Should minimal blood glucose variability become the gold standard of glycemic control? J Diabetes Complications 2005;19(3):178-81. DOI: 10.1016/j. jdiacomp.2004.10.001.

  24. Monnier L, Colette C, Wojtusciszyn A, Dejager S, Renard E, Molinari N, et al. Toward defining the threshold between low and high glucose variability in diabetes. Diabetes Care 2017;40(7):832-838. doi: 10.2337/dc16-1769.




2020     |     www.medigraphic.com